8rgf

From Proteopedia

Arginase 2 in complex with inhibitor

Structural highlights

8rgf is a 3 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA. For a guided tour on the structure components use FirstGlance.
Method:	X-ray diffraction, Resolution 1.86Å
Ligands:	,
Resources:	FirstGlance, OCA, PDBe, RCSB, PDBsum, ProSAT

Function

ARGI2_HUMAN May play a role in the regulation of extra-urea cycle arginine metabolism and also in down-regulation of nitric oxide synthesis. Extrahepatic arginase functions to regulate L-arginine bioavailability to NO synthase. Since NO synthase is found in the penile corpus cavernosum smooth muscle, the clitoral corpus cavernosum and the vagina, arginase II plays a role in both male and female sexual arousal. It is therefore a potential target for the treatment of male and female sexual arousal disorders.

Publication Abstract from PubMed

Arginase is a promising immuno-oncology target that can restore the innate immune response. However, it's highly polar active site often requires potent inhibitors to mimic amino acids, leading to poor passive permeability and low oral exposure. Using structure-based drug design, we discovered a novel proline-based arginase inhibitor (10) that was potent but had low oral bioavailability in rat. This issue was addressed by incorporating amino acids to target PepT1/2 active transport, followed by in vivo hydrolysis post absorption. The hydrolysis rate was highly tunable, and the valine prodrug (19) showed the best balance of stability and exposure of the potent payload. Dosing of 19 in mouse xenograft models significantly increased arginine in the tumor microenvironment, resulting in tumor growth inhibition as a monotherapy and in combination with an anti-PD-L1 antibody. Compound 19 (AZD0011) displays good pharmacokinetics and was selected as a clinical drug candidate for cancer.

Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer.,Mlynarski SN, Aquila BM, Cantin S, Cook S, Doshi A, Finlay MRV, Gangl ET, Grebe T, Gu C, Kawatkar SP, Petersen J, Pop-Damkov P, Schuller AG, Shao W, Shields JD, Simpson I, Tavakoli S, Tentarelli S, Throner S, Wang H, Wang J, Wu D, Ye Q J Med Chem. 2024 Nov 21. doi: 10.1021/acs.jmedchem.4c02309. PMID:39572889^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

References

↑ Mlynarski SN, Aquila BM, Cantin S, Cook S, Doshi A, Finlay MRV, Gangl ET, Grebe T, Gu C, Kawatkar SP, Petersen J, Pop-Damkov P, Schuller AG, Shao W, Shields JD, Simpson I, Tavakoli S, Tentarelli S, Throner S, Wang H, Wang J, Wu D, Ye Q. Discovery of (2R,4R)-4-((S)-2-Amino-3-methylbutanamido)-2-(4-boronobutyl)pyrrolidine-2-carboxylic Acid (AZD0011), an Actively Transported Prodrug of a Potent Arginase Inhibitor to Treat Cancer. J Med Chem. 2024 Nov 21. PMID:39572889 doi:10.1021/acs.jmedchem.4c02309